Inflammatory Bowel Disease-Associated Changes in the Gut: Focus on Kazan Patients.

Autor:	Lo Sasso G; Philip Morris International Research and Development, Philip Morris Products S.A., Neuchâtel, Switzerland., Khachatryan L; Philip Morris International Research and Development, Philip Morris Products S.A., Neuchâtel, Switzerland., Kondylis A; Philip Morris International Research and Development, Philip Morris Products S.A., Neuchâtel, Switzerland., Battey JND; Philip Morris International Research and Development, Philip Morris Products S.A., Neuchâtel, Switzerland., Sierro N; Philip Morris International Research and Development, Philip Morris Products S.A., Neuchâtel, Switzerland., Danilova NA; Kazan Federal University, Institute of Fundamental Medicine and Biology, Kazan, Tatarstan, Russian Federation., Grigoryeva TV; Kazan Federal University, Institute of Fundamental Medicine and Biology, Kazan, Tatarstan, Russian Federation., Markelova MI; Kazan Federal University, Institute of Fundamental Medicine and Biology, Kazan, Tatarstan, Russian Federation., Khusnutdinova DR; Kazan Federal University, Institute of Fundamental Medicine and Biology, Kazan, Tatarstan, Russian Federation., Laikov AV; Kazan Federal University, Institute of Fundamental Medicine and Biology, Kazan, Tatarstan, Russian Federation., Salafutdinov II; Kazan Federal University, Institute of Fundamental Medicine and Biology, Kazan, Tatarstan, Russian Federation., Romanova YD; Kazan Federal University, Institute of Fundamental Medicine and Biology, Kazan, Tatarstan, Russian Federation., Siniagina MN; Kazan Federal University, Institute of Fundamental Medicine and Biology, Kazan, Tatarstan, Russian Federation., Vasiliev IY; Kazan Federal University, Institute of Fundamental Medicine and Biology, Kazan, Tatarstan, Russian Federation., Boulygina EA; Kazan Federal University, Institute of Fundamental Medicine and Biology, Kazan, Tatarstan, Russian Federation., Solovyeva VV; Kazan Federal University, Institute of Fundamental Medicine and Biology, Kazan, Tatarstan, Russian Federation., Garanina EE; Kazan Federal University, Institute of Fundamental Medicine and Biology, Kazan, Tatarstan, Russian Federation., Kitaeva KV; Kazan Federal University, Institute of Fundamental Medicine and Biology, Kazan, Tatarstan, Russian Federation., Ivanov KY; Kazan Federal University, Institute of Fundamental Medicine and Biology, Kazan, Tatarstan, Russian Federation., Chulpanova DS; Kazan Federal University, Institute of Fundamental Medicine and Biology, Kazan, Tatarstan, Russian Federation., Kletenkov KS; Kazan Federal University, Institute of Fundamental Medicine and Biology, Kazan, Tatarstan, Russian Federation., Valeeva AR; Department of Clinical Immunology and Allergology, Kazan State Medical University, Kazan, Tatarstan, Russian Federation., Odintsova AK; Department of Gastroenterology, Republican Clinical Hospital of Tatarstan Republic, Kazan, Tatarstan, Russian Federation., Ardatskaya MD; Central State Medical Academy of Administrative Department of the President of the Russian Federation, Moscow, Russian Federation., Abdulkhakov RA; Department of Clinical Immunology and Allergology, Kazan State Medical University, Kazan, Tatarstan, Russian Federation., Ivanov NV; Philip Morris International Research and Development, Philip Morris Products S.A., Neuchâtel, Switzerland., Peitsch MC; Philip Morris International Research and Development, Philip Morris Products S.A., Neuchâtel, Switzerland., Hoeng J; Philip Morris International Research and Development, Philip Morris Products S.A., Neuchâtel, Switzerland., Abdulkhakov SR; Kazan Federal University, Institute of Fundamental Medicine and Biology, Kazan, Tatarstan, Russian Federation.
Jazyk:	angličtina
Zdroj:	Inflammatory bowel diseases [Inflamm Bowel Dis] 2021 Feb 16; Vol. 27 (3), pp. 418-433.
DOI:	10.1093/ibd/izaa188
Abstrakt:	Background: Several studies have highlighted the role of host-microbiome interactions in the pathogenesis of inflammatory bowel disease (IBD), resulting in an increasing amount of data mainly focusing on Western patients. Because of the increasing prevalence of IBD in newly industrialized countries such as those in Asia, the Middle East, and South America, there is mounting interest in elucidating the gut microbiota of these populations. We present a comprehensive analysis of several IBD-related biomarkers and gut microbiota profiles and functions of a unique population of patients with IBD and healthy patients from Kazan (Republic of Tatarstan, Russia). Methods: Blood and fecal IBD biomarkers, serum cytokines, and fecal short-chain fatty acid (SCFA) content were profiled. Finally, fecal microbiota composition was analyzed by 16S and whole-genome shotgun sequencing. Results: Fecal microbiota whole-genome sequencing confirmed the presence of classic IBD dysbiotic features at the phylum level, with increased abundance of Proteobacteria, Actinobacteria, and Fusobacteria and decreased abundance of Firmicutes, Bacteroidetes, and Verrucomicrobia. At the genus level, the abundance of both fermentative (SCFA-producing and hydrogen (H2)-releasing) and hydrogenotrophic (H2-consuming) microbes was affected in patients with IBD. This imbalance was confirmed by the decreased abundance of SCFA species in the feces of patients with IBD and the change in anaerobic index, which mirrors the redox status of the intestine. Conclusions: Our analyses highlighted how IBD-related dysbiotic microbiota-which are generally mainly linked to SCFA imbalance-may affect other important metabolic pathways, such as H2 metabolism, that are critical for host physiology and disease development. (© 2020 Crohn’s & Colitis Foundation. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu